Over 80 pharma companies collaborate on advancing RNA-based therapies, driving market growth
From GlobeNewswire: 2024-10-16 13:00:00
Over 80 pharma companies are collaborating to advance RNA-based therapeutics, driving market growth in mRNA, siRNA, and antisense oligonucleotide therapies. DelveInsight’s report highlights key players like Novartis, Moderna, and Janssen, evaluating 100+ RNA therapies in various stages of development focusing on oncology, infectious diseases, and genetic disorders. RNA therapies target gene expression at the mRNA level, offering precise treatment for a range of diseases. While promising, challenges in RNA delivery and production costs remain key hurdles. Novartis’s LEQVIO is a notable siRNA therapy targeting PCSK9 to lower LDL cholesterol. RNA therapies market growth is fueled by advances in biotechnology, with potential to treat genetic disorders, cancers, and infectious diseases. Major pharmaceutical companies and biotechs like Moderna, Alnylam Pharmaceuticals, and BioNTech are leading the way in RNA therapeutic development and expanding pipelines through partnerships. Regulatory agencies are fast-tracking approval for RNA-based treatments for life-threatening or rare diseases. Key pipeline RNA therapies include ARO-APOC3, Cemdisiran, Sepofarsen, AB-729, and HRS 5635, targeting a range of indications from hyperlipoproteinemia to cardiovascular disorders. Recent developments include Rgenta Therapeutics’ IND clearance for RGT-61159 in cancer treatment and research collaborations exploring RNA exon editing therapeutics for neurological diseases. Achilles Therapeutics and Arcturus Therapeutics are collaborating on personalized cancer vaccines, while Ipsen and Skyhawk Therapeutics focus on rare neurological diseases. MiNA Therapeutics and Nippon Shinyaku Co. are targeting rare neurodegenerative diseases with RNAa therapeutic candidates, and Boehringer Ingelheim teams up with Ribo to develop RNAi therapeutics for NASH/MASH. To keep pace with the evolving RNA therapies landscape, sign up for DelveInsight’s RNA Therapies Competitive Landscape Report.
Read more at GlobeNewswire: 80+ Pharma Companies Unite to Shape the Future of RNA-Based